Market Overview

UPDATE: Soaring 19%, Deutsche Bank Initiates Coverage on Arrowhead Research

Related ARWR
Arrowhead Files For Regulatory Permission To Begin Phase 1 Trial Of RNAi Therapeutic ARC-AAT
Arrowhead Offers Data on ARC-520, ARC-AAT at AASLD The Liver Meeting

Rating reports today from Deutsche Bank includes analyst Alethia Young initiating coverage on Arrowhead Research (NASDAQ: ARWR). The initial rating is a Buy with a price target of $45.

Young notes, "Arrowhead is an early stage platform company that we believe could have the market cap potential of $4-5B as it becomes de-risked. The company's lead target is ARC-520 for Hepatitis B (HBV). Our HBV deep dive suggests ARC-520 could grow the market from $2B to $5B and see $5.2B peak sales WW."

Some risks that were mentioned includes possible safety and efficacy issues relating to drug and platform technology. Possible clinical delays on ARC-520 may also hinder then ability of ARWR to reach its potential.

ARWR closed previous trading session at $21.14 and is currently trading around the $25.23 mark, up over 19%. The price target of $45 displays a 170% upside from current trading prices.

Latest Ratings for ARWR

DateFirmActionFromTo
Oct 2014RBC CapitalDowngradesOutperformSector Perform
Oct 2014Deutsche BankMaintainsBuy
Mar 2014Deutsche BankInitiates Coverage onBuy

View More Analyst Ratings for ARWR
View the Latest Analyst Ratings

Posted-In: Deutsche BankNews Price Target Initiation Markets Analyst Ratings

 

Related Articles (ARWR)

Around the Web, We're Loving...

Get Benzinga's Newsletters